drugset

drugset / Trial / NCT01104376

Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy Volunteers

NCT01104376 ↗

Completed 61 enrolled Indiana University National Institute of General Medical Sciences (NIGMS) · collab National Institutes of Health (NIH) · collab

NaSingle-groupOpen-labelScreening

Summary

The purpose of this study is to see if administration of medicines and genetic differences affects the activity of a liver enzyme called CYP2B6 in healthy volunteers.

Timeline

Start: 2010-03
Primary completion: 2011-04
Completion: 2013-04

Publications

Desta Z, Metzger IF, Thong N, Lu JB, Callaghan JT, Skaar TC, Flockhart DA, Galinsky RE. Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers. Antimicrob Agents Chemother. 2016 Oct 21;60(11):6813-6822. doi: 10.1128/AAC.01000-16. Print 2016 Nov.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Efavirenz	Other / unclassified	100 mg	Oral
Subject	Voriconazole	Small molecule	200 mg	—

Indications